Malignant tumor (lung cancer, gastric cancer, etc)
Conditions
Interventions
None listed
Sponsors
Department of Clinical Pharmacology and Genitics, School of Pharmaceutical Science, Univercity of Shizuoka
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Malignant tumor patients except for hematopoietic malignancy 2) Patients who receive the chemotherapy involving cisplatin (>= 50 mg/m2) 3) 20 years-old over at the time of giving informed consent 4) ECOG PS 0-2 5) Adequate organ function obtained within 2 weeks prior to registration. Laboratory values must be as follows; T-Bill <= 1.5 mg/dL AST <= 100 IU/L ALT <= 100 IU/L 6)Informed consent by the document
Exclusion criteria
Exclusion criteria: 1) Known prior severe hypersensitivity to platinum-containing drug, 5HT3 receptor antagonist, corticosteroids and aprepitant 2) Patients who do not have enough whole body state to the antineoplastic agents treatment 3) Pregnant, breastfeeding or expecting woman 4) Patient with severe uncontrollable diabetes mellitus 5) Known symptomatic brain metastasis 6) Patients who take a medicine regularly such as corticosteroids, dopamine D2-receptor antagonist, phenothiazine tranquilizers, antihistamine drugs and benzodiazepine etc 7) Other clinical difficulties in this study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Proportion of complete response (defined as no emesis and no rescue treatment). [Time Frame: overall; 0-120hr(during and post chemotherapy), acute phase;0-24hr, delayed phase 24-120hr] | — |
Countries
Japan
Contacts
Public ContactDaiki Tsuji
Univercity of Shizuoka School of Pharmaceutical Science
Outcome results
None listed